GLUE financials
Monte Rosa Therapeutics (GLUE) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
GLUE income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $123.67M | $115.32M | -$54.21M | -$38.63M | -0.59 |
| 2024 | $75.62M | $67.50M | -$81.11M | -$72.70M | -0.98 |
| 2023 | $0.00 | -$6.22M | -$143.31M | -$135.35M | -2.63 |
| 2022 | $0.00 | $0.00 | -$112.38M | -$108.50M | -2.30 |
| 2021 | $0.00 | $0.00 | -$72.88M | -$73.96M | -1.59 |
| 2020 | $0.00 | -$537.00K | -$28.01M | -$35.88M | -0.82 |
- GLUE revenue was $123.67M in fiscal 2025, net income -$38.63M.
Updated 2026-11-07 11:55 UTC